Skip to main content

Table 6 Changes in alkaline phosphatase at different time points

From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]

  3–6 months 1 year 2 years 3 years
Number of patients and change in alkaline         
phosphatase Active Placebo Active Placebo Active Placebo Active Placebo
n 694 721 558 595 444 473 360 362
Decrease ≥ 20% 81.0 3.1 72.8 5.1 76.4 11.0 87.5 21.3
Decrease 0–20% 15.9 44.1 21.7 37.2 19.4 40.9 8.9 43.2
Increase 3.2 52.8 5.6 57.7 4.3 48.1 3.6 35.5
  1. Percentage changes in alkaline phosphatase by treatment group between baseline and 3–6 months, and 1, 2 and 3 years, as a measure of compliance.